Dec 16th 2020
  • Share:

BayMark Announces Acquisition of Three Opioid Treatment Programs in Louisiana

BayMark Health Services has acquired Choices of Louisiana, an Opioid Treatment company consisting of three Opioid Treatment Programs (OTPs), one in Alexandria and two in the New Orleans, LA market. The programs provide medication-assisted treatment (MAT) for opioid addiction supported by substance use counseling. For more than 20 years, Choices has been recognized as an effective, trusted provider of proven treatment for opioid addiction, and they will continue to provide that same level of service under the BayMark brand BAART Programs which currently operate a location in Breaux Bridge, LA.

BAART Programs provide medically-supervised, medication-assisted treatment (MAT), utilizing methadone or buprenorphine, as well as counseling and support services. Those services include addiction education, relapse prevention, in-house lab testing, coordinated care for pregnant women and linkages to community resources. Our goal is to deliver comprehensive programs to assist patients on their path to recovery.

BayMark now operates four OTP clinics serving the residents of Louisiana who struggle with opioid use disorder. In addition, BayMark operates eight outpatient, office-based opioid treatment (OBOT) programs in Louisiana offering telehealth or in-office clinician appointments. The programs are medication-based, but prescriptions for buprenorphine/Suboxone® are provided which can be filled at the local pharmacy. All BayMark programs offer in-house or referral-based counseling services and other psychosocial interventions to support recovery.

David K. White, Ph.D, Chief Executive Office of BayMark Health Services shared, “The need for opioid addiction treatment options has never been greater as we stand at the intersection of both the Opioid Epidemic and the impact of the COVID-19 Pandemic. BayMark sees the need for expanded access to evidence-based treatment and partners with providers who have established a foundation of excellence in their clinical practices. The Choices organization has established a deep commitment to patient care that makes this a great opportunity for BayMark. We are excited to continue their legacy, now as a member of the BayMark/BAART family.”

For more information, to make an appointment or refer a patient, visit


About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to 62,000+ patients in recovery from substance use disorder across the United States and Canada. Our outpatient programs deliver medically-supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances.

The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

Now Available: BayMark's 2023 Treatment Outcomes ReportGet the Whitepaper